Dyax Announces FDA Approval of Kalbitor (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Dyax Announces FDA Approval of Kalbitor (ecallantide) for the
Treatment of Acute Attacks of Hereditary Angioedema in Patients 16
Years of Age and Older
December 2, 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 1, 2009 - Dyax Corp. announced
today that the U.S. Food and Drug Administration (FDA) has granted
approval for Kalbitor (ecallantide) for the treatment of acute attacks
of hereditary angioedema (HAE) in patients 16 years of age and older.
HAE is a rare, genetic disorder characterized by severe, debilitating
and often painful swelling, which can occur in the abdomen, face,
hands, feet and airway. Kalbitor, a potent, selective and reversible
plasma kallikrein...
Treatment of Acute Attacks of Hereditary Angioedema in Patients 16
Years of Age and Older
December 2, 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 1, 2009 - Dyax Corp. announced
today that the U.S. Food and Drug Administration (FDA) has granted
approval for Kalbitor (ecallantide) for the treatment of acute attacks
of hereditary angioedema (HAE) in patients 16 years of age and older.
HAE is a rare, genetic disorder characterized by severe, debilitating
and often painful swelling, which can occur in the abdomen, face,
hands, feet and airway. Kalbitor, a potent, selective and reversible
plasma kallikrein...
Comentarios
Publicar un comentario